Microglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders.
Inventor First Name:
Jau-Shyong
Liya
Guorong
MIchelle
Wei
Po-See
Giia-Shuen
Inventor Last Name:
Hong
Qin
Li
Block
Zhang
Chen
Peng
E Number Only:
E-130-2004
Inv Is lead:
Pat Filing Date:
2005-05-12
2014-07-03
2011-12-13
2004-05-12
2006-11-13
Patent Issue Date:
2016-11-22
2014-08-05
2012-01-03
Patent Number:
9,498,511
8,796,302
8,088,787
Provider Technology ID:
1010
Patent Application:
PCT/US2005/16691
14/323,557
13/324,876
60/570,566
11/596,296
LPM Zip:
20892
LPM Organization:
NIH Office of Technology Transfer
LPM Phone:
301-594-4095
LPM State:
MD
LPM Suffix:
Ph.D.
Publication Caption:
PMID 10991969
Publication Link:
https://pubmed.ncbi.nlm.nih.gov/10991969/
Updated On:
Wednesday, March 10, 2021
Publication Title:
Liu B, et al.
LPM Last Name:
Choudhry
LPM FIrst Name:
Vidita
Development Stage:
Date Published:
Wednesday, March 10, 2021
Development Status:
- Early-stage
- Pre-clinical
- In vitro data available
- In vivo data available (animal)
DTDT Classification:
Internal Medicine
Therapeutics
Anti-Inflammatory (including Autoimmune)
Central Nervous System
Therapeutics
Antiparkinsonian
Brochure - In-vitro Data
Central Nervous System
Therapeutic (biologic)
Therapeutic (small molecule)
Early-stage
In vitro data available
In vivo data available (animal)
DTDT Description:
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Therapeutics: Anti-Inflammatory
Central Nervous System
Central Nervous System - Therapeutics
Central Nervous System - Therapeutics - Neurological Therapeutics: Antiparkinsonian
In-vitro Data
Central Nervous System
Therapeutic (biologic)
Therapeutic (small molecule)
Early-stage
In vitro data available
In vivo data available (animal)
Collaboration Sought:
Yes
Collaboration Opportunity:
The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Sharon Soucek, Ph.D. at sharon.soucek@nih.gov
Advantages:
- These compounds are active at ultra-low concentrations.
Application:
Applications:
- Therapeutic treatment of Parkinson, Alzheimers and other degenerative CNS disorders.
NIH Ref. No.:
E-130-2004-0
IC:
NIEHS
LPM Address:
BG 31 RM 4A29 MSC 247
31 CENTER DR
Inventor Lab URL:
https://irp.nih.gov/pi/jau-shyong-hong
LPM City:
Bethesda
LPM Email:
vidita.choudhry@nih.gov
Inventor IC:
NIEHS
NIEHS
NIEHS
NIEHS
NIEHS
NIEHS
NIEHS
Institute or Center:
Lead Inventor:
Disease Area:
